Publications by authors named "Y Habu"
Objective: Therapy-related myeloid neoplasms (t-MNs) are often fatal and arise as late complications of previous anticancer drug treatment. No single-center case series has examined t-MNs in epithelial ovarian cancer (EOC).
Methods: All patients with EOC treated at Chiba University Hospital between 2000 and 2021 were included.
Background: Optimised antithrombotic therapy requires clinical experience and an understanding of the current guidelines. This retrospective study aimed to evaluate whether pharmacist interviews and interventions with patients taking oral antithrombotic drugs in the pharmaceutical outpatient cardiology clinic had favourable clinical outcomes including decreased bleeding.
Methods: The participants included patients visiting the outpatient clinic of cardiovascular internal medicine at the Kobe University Hospital from January-December 2017, and were taking oral antithrombotic medication.
Article Synopsis
- No effective therapeutic drugs are available for nonalcoholic steatohepatitis (NASH), a liver condition that progresses from nonalcoholic fatty liver; PPAR subtypes (α, δ, γ) are potential targets for treatment.
- Current clinical trials are examining lanifibranor (a pan agonist) and saroglitazar (a dual agonist), while the development of other dual/pan agonists like seladelpar and elafibranor has been halted due to side effects or lack of efficacy.
- The study evaluated the binding and activation of lanifibranor, seladelpar, and elafibranor on PPARs using several assays and high-resolution cocrystal
Beige adipocytes are transiently induced during early postnatal period in mice. Previous studies have suggested that, unlike in adults, the induction is independent of the sympathetic nerve activity; however, the mechanism is yet unknown. Here, we showed that beige adipocytes are induced during the preweaning period in association with the formation of microbiota in mice.
View Article and Find Full Text PDFWe conducted a phase Ib study to examine the safety of a combination of carbon-ion RT (CIRT) with durvalumab (MEDI4736; AstraZeneca) in patients with locally advanced cervical cancer. This was an open-label, single-arm study with a modified 3 + 3 design. Patients with newly diagnosed histologically proven locally advanced cervical cancer were enrolled.
View Article and Find Full Text PDF